

**September 27, 2024**

National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai-400051

BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal  
Street Fort, Mumbai- 400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

**Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR') regarding the email received from BSE Limited on September 26, 2024.**

Dear Sir/Madam,

In continuation to our letter submitted with BSE Limited (BSE) on April 05, 2024 and National Stock Exchange of India Limited on April 06, 2024 subjected as 'Explanation for the delay under Regulation 30 regarding the aforesaid intimation dated December 14, 2023 submitted by the Company' read with the letter submitted with both Stock Exchanges, dated September 26, 2024, subjected as 'Warning letter under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR') and in accordance with the BSE email dated September 26, 2024 for disclosing the warning letter, as issued by BSE, for the delayed intimation of resignation of erstwhile Company Secretary, please find enclosed herewith the copy of Warning Letter in this regard.

Further, the details required in terms of Schedule III – Sub-Para 20 of Para A of Part A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 issued in this regard, are given in the annexure enclosed herewith as **Annexure-I**.

You are requested to take the above information on record.

Thanking You,  
For **Orchid Pharma Limited**

**Kapil Dayya**  
**Company Secretary & Compliance Officer**  
**Mem. No. F10698**

*Encl: as above*

**Annexure- I**

**Information as required under Regulation 30, Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Information</b>
1	name of the authority	BSE Limited
2	nature and details of the action(s) taken, initiated or order(s) passed	Warning Letter issued for delayed intimation for resignation of Company Secretary
3	date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	September 26, 2024
4	details of the violation(s)/contravention(s) committed or alleged to be committed;	Delayed intimation for resignation of Company Secretary beyond the timeline prescribed under SEBI LODR
5	impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact

LIST/COMP/JP/532/2024-25

Date: September 26, 2024

To,  
The Company Secretary  
**Orchid Pharma Limited (524372)**  
Orchid Towers 313, Valluvarkottam,  
High Road Nugambakkam,  
Chennai – 600034

**Sub: Warning letter under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR')**

Dear Sir/Madam,

This is in reference to the disclosure submitted by Orchid Pharma Limited ('the Company') on December 14, 2023, with respect to "Resignation of Company Secretary & Compliance Officer of the Company".

As per Regulation 30 read with sub-para 7 of Para A Part A of Schedule III of SEBI LODR and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, the listed entity shall inform the resignation of directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), senior management, Auditor and Compliance Officer **not later than 24 hours from occurrence of the event.**

In the above case, the Exchange has observed that the intimation for resignation of the Company Secretary was submitted with delay beyond the timeline prescribed in the aforesaid provisions.

The aforesaid non-compliance on your part is viewed seriously. You are hereby warned and advised to be careful in future, exercise due caution and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of the warning letter on the Stock Exchanges where it is listed on. Additionally, the Company is advised to place before their Board of Directors this warning letter and the corrective measures taken by the company to avoid such lapses in future.

Yours faithfully,  
**For BSE Limited**



**Jaikishan Pahlani**  
**AGM - Listing Compliance**